Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome

Research output: Contribution to journalArticleResearchpeer-review

48 Citations (Scopus)
Original languageEnglish
Pages (from-to)1020 - 1025
Number of pages6
JournalCurrent Opinion in Investigational Drugs
Volume7
Issue number11
Publication statusPublished - 2006
Externally publishedYes

Cite this

@article{b348991d9c5041909dd3a6d7dd36473a,
title = "Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome",
author = "Changhai Ding",
year = "2006",
language = "English",
volume = "7",
pages = "1020 -- 1025",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Thomson Reuters (Prous Science)",
number = "11",

}

Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. / Ding, Changhai.

In: Current Opinion in Investigational Drugs, Vol. 7, No. 11, 2006, p. 1020 - 1025.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome

AU - Ding, Changhai

PY - 2006

Y1 - 2006

UR - http://eprints.utas.edu.au/3610/1/vx-702.pdf

M3 - Article

VL - 7

SP - 1020

EP - 1025

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 11

ER -